Cloud-Magnetic Resonance Imaging System: In the Era of 6G and Artificial Intelligence

Magnetic Resonance Imaging (MRI) plays an important role in medical diagnosis, generating petabytes of image data annually in large hospitals. This voluminous data stream requires a significant amount of network bandwidth and extensive storage infrastructure. Additionally, local data processing demands substantial manpower and hardware investments. Data isolation across different healthcare institutions hinders cross-institutional collaboration in clinics and research. In this work, we anticipate an innovative MRI system and its four generations that integrate emerging distributed cloud computing, 6G bandwidth, edge computing, federated learning, and blockchain technology. This system is called Cloud-MRI, aiming at solving the problems of MRI data storage security, transmission speed, AI algorithm maintenance, hardware upgrading, and collaborative work. The workflow commences with the transformation of k-space raw data into the standardized Imaging Society for Magnetic Resonance in Medicine Raw Data (ISMRMRD) format. Then, the data are uploaded to the cloud or edge nodes for fast image reconstruction, neural network training, and automatic analysis. Then, the outcomes are seamlessly transmitted to clinics or research institutes for diagnosis and other services. The Cloud-MRI system will save the raw imaging data, reduce the risk of data loss, facilitate inter-institutional medical collaboration, and finally improve diagnostic accuracy and work efficiency.Comment: 4pages, 5figures, letter

Characterization of Cajanus scarabaeoides growing in Yuanjiang county of Yunnan province in China

In Yuanjiang, Yunnan, China, C. scarabaeoides is found in abundance in open grasslands and dry scrub vegetation on hill slopes and ridges between cultivated fields. It is also located along roadsides, foot paths or convex rides where reasonable amount of sunlight is available. This creeper-climber, supported by grass and small shrubs have: either straight or winding branches which are woody at the base; pinnately trifoliate leaves with white-pubescent lower and upper surfaces; obovate end leaflet; short racemes; indeterminate and sporadic flowering habit; oblong, purple to dark purple pods; rectangular to rounded seeds; and yellow or creamish yellow flowers with dense sun-red veins. Its mean protein content is 21.88% in the seed and 13.23% in the dried leaves. It may be used as medicine for diarrhoea in cattle, and as a traditional Chinese medicine for improving indigestion and diuresis

Electrically bioactive coating on Ti with bi-layered SnO2-TiO2 hetero-structure for improving osteointegration

SnO2–TiO2 surface with the bi-layered structure on Ti provides internal electric stimulation to promote osteointegration of implant.</p

Enhanced Osseointegration of Hierarchically Structured Ti Implant with Electrically Bioactive SnO₂-TiO₂ Bilayered Surface

The poor osseointegration of Ti implant significantly compromise its application in load-bearing bone repair and replacement. Electrically bioactive coating inspirited from heterojunction on Ti implant can benefit osseointegration but cannot avoid the stress shielding effect between bone and implant. To resolve this conflict, hierarchically structured Ti implant with electrically bioactive SnO2–TiO2 bilayered surface has been developed to enhance osseointegration. Benefiting from the electric cue offered by the built-in electrical field of SnO2–TiO2 heterojunction and the topographic cue provided by the hierarchical surface structure to bone regeneration, the osteoblastic function of basic multicellular units around the implant is significantly improved. Because the individual TiO2 or SnO2 coating with uniform surface exhibits no electrical bioactivity, the effects of electric and topographic cues to osseointegration have been decoupled via the analysis of in vivo performance for the placed Ti implant with different surfaces. The developed Ti implant shows significantly improved osseointegration with excellent bone–implant contact, improved mineralization of extracellular matrix, and increased push-out force. These results suggest that the synergistic strategy of combing electrical bioactivity with hierarchical surface structure provides a new platform for developing advanced endosseous implants

Evaluation of the IP-10 mRNA release assay for diagnosis of TB in HIV-infected individuals

HIV-infected individuals are susceptible to Mycobacterium tuberculosis (M.tb) infection and are at high risk of developing active tuberculosis (TB). Interferon-gamma release assays (IGRAs) are auxiliary tools in the diagnosis of TB. However, the performance of IGRAs in HIV-infected individuals is suboptimal, which limits clinical application. Interferon-inducible protein 10 (IP-10) is an alternative biomarker for identifying M.tb infection due to its high expression after stimulation with M.tb antigens. However, whether IP-10 mRNA constitutes a target for the diagnosis of TB in HIV-infected individuals is unknown. Thus, we prospectively enrolled HIV-infected patients with suspected active TB from five hospitals between May 2021 and May 2022, and performed the IGRA test (QFT-GIT) alongside the IP-10 mRNA release assay on peripheral blood. Of the 216 participants, 152 TB patients and 48 non-TB patients with a conclusive diagnosis were included in the final analysis. The number of indeterminate results of IP-10 mRNA release assay (13/200, 6.5%) was significantly lower than that of the QFT-GIT test (42/200, 21.0%) (P = 0.000026). IP-10 mRNA release assay had a sensitivity of 65.3% (95%CI 55.9% – 73.8%) and a specificity of 74.2% (95%CI 55.4% – 88.1%), respectively; while the QFT-GIT test had a sensitivity of 43.2% (95%CI 34.1% – 52.7%) and a specificity of 87.1% (95%CI 70.2% – 96.4%), respectively. The sensitivity of the IP-10 mRNA release assay was significantly higher than that of QFT-GIT test (P = 0.00062), while no significant difference was detected between the specificities of these two tests (P = 0.198). The IP-10 mRNA release assay showed a lower dependence on CD4+ T cells than that of QFT-GIT test. This was evidenced by the fact that the QFT-GIT test had a higher number of indeterminate results and a lower sensitivity when the CD4+ T cells counts were decreased (P &lt; 0.05), while no significant difference in the number of indeterminate results and sensitivity were observed for the IP-10 mRNA release assay among HIV-infected individuals with varied CD4+T cells counts (P &gt; 0.05). Therefore, our study suggested that M.tb specific IP-10 mRNA is a better biomarker for diagnosis of TB in HIV-infected individuals